Amylin Pharmaceuticals Announces Positive Results From Dose-Ranging Clinical Study Of Pramlintide/Metreleptin Combination Treatment For Obesity
Links shared publicly online about this topic.
- 1,907total visits
Amylin Pharmaceuticals Announces Positive Results From Dose-Ranging Clinical Study Of Pramlintide/Metreleptin Combination Treatment For Obesity
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of t
View full resource at medicalnewstoday.com
Most Recently Shared on July 10, 2009 at 6:37 pm By:
Intriguing developments from Amylin for treatment of #obesity - about 18 pounds in seven months. http://tinyurl.com/l7qrs4 #weightloss
Advertisement
